Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459757 · ClinicalTrials.gov registry record
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
A clinical trial of GIST, sponsored by Pfizer.
- Completed
- Registry status
- 322
- Enrollment target
- 20
- Study locations
NCT01459757 is a study of GIST that has completed, run by Pfizer. The registered enrollment target is 322 participants, above the 96-participant average among 8 other GIST trials with a reported enrollment target (235% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01459757, a study of GIST, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 322 participants
- Enrollment target
- 20
- Study locations
Study Summary
Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
Conditions Studied
Interventions
- OTHER non-interventional
Study Locations (20)
Florida
- Davis Cancer Pavilion and Shands Medical Plaza - Gainesville
- Shands Cancer Hospital at the University of Florida - Gainesville
- Shands Hospital at the University of Florida - Gainesville
- Moffitt Cancer Center - Tampa
Other
- UZ Leuven - Leuven
- Herlev Hospital - Herlev
- Helsingin yliopistollinen keskussairaala/Syopatautien klinikka - Helsinki
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Washington
- Seattle Cancer Care Alliance - Seattle
- University of Washington - Seattle
California
- City of Hope - Duarte
District of Columbia
- Washington Hospital Center - Washington D.C.
Minnesota
- Masonic Cancer Center - Clinical Trials Office - Minneapolis
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01459757
The ClinicalTrials.gov registry entry for NCT01459757 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 8 other GIST trials with a reported enrollment target (235% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GIST appearing as the primary indexed condition, and to 1 intervention - of which non-interventional is the first listed.
NCT01459757 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01459757 about?
NCT01459757 is a clinical study titled "Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib". Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
What is the current status of trial NCT01459757?
This trial is currently completed. The enrollment target is 322 participants. The study started on 2011-10. Estimated completion is 2013-04.
What conditions does trial NCT01459757 study?
This clinical trial studies the following conditions: GIST.
What interventions are being tested in trial NCT01459757?
The interventions under investigation include: non-interventional (OTHER).
Who is sponsoring clinical trial NCT01459757?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01459757 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GIST
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RECRUITING · Phase 1
-
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
RECRUITING · Phase 1
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.